Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation
M Sterneck, G M Kaiser, N Heyne, N Richter, F Rauchfuss, A Pascher, P Schemmer, L Fischer, C G Klein, S Nadalin, F Lehner, U Settmacher, P Neuhaus, D Gotthardt, M Loss, S Ladenburger, E M Paulus, M Mertens, H J Schlitt, M Sterneck, G M Kaiser, N Heyne, N Richter, F Rauchfuss, A Pascher, P Schemmer, L Fischer, C G Klein, S Nadalin, F Lehner, U Settmacher, P Neuhaus, D Gotthardt, M Loss, S Ladenburger, E M Paulus, M Mertens, H J Schlitt
Abstract
The feasibility of de novo everolimus without calcineurin inhibitor (CNI) therapy following liver transplantation was assessed in a multicenter, prospective, open-label trial. Liver transplant patients were randomized at 4 weeks to start everolimus and discontinue CNI, or continue their current CNI-based regimen. The primary endpoint was adjusted estimated GFR (eGFR; Cockcroft-Gault) at month 11 post randomization. A 24-month extension phase followed 81/114 (71.1%) of eligible patients to month 35 post randomization. The adjusted mean eGFR benefit from randomization to month 35 was 10.1 mL/min (95% confidence interval [CI] -1.3, 21.5 mL/min, p = 0.082) in favor of CNI-free versus CNI using Cockcroft-Gault, 9.4 mL/min/1.73 m(2) (95% CI -0.4, 18.9, p = 0.053) with Modification of Diet in Renal Disease (four-variable) and 9.5 mL/min/1.73 m(2) (95% CI -1.1, 17.9, p = 0.028) using Nankivell. The difference in favor of the CNI-free regimen increased gradually over time due to a small progressive decline in eGFR in the CNI cohort despite a reduction in CNI exposure. Biopsy-proven acute rejection, graft loss and death were similar between groups. Adverse events led to study drug discontinuation in five CNI-free patients and five CNI patients (12.2% vs. 12.5%, p = 1.000) during the extension phase. Everolimus-based CNI-free immunosuppression is feasible following liver transplantation and patients benefit from sustained preservation of renal function versus patients on CNI for at least 3 years.
Keywords: Calcineurin inhibitor; everolimus; liver transplantation; long-term; withdrawal.
© 2014 The Authors. American Journal of Transplantation Published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons.
Figures
References
- Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940.
- Lamattina JC, Mezrich JD, Fernandez LA, et al. Native kidney function following liver transplantation using calcineurin inhibitors: Single-center analysis with 20 years of follow-up. Clin Transplant. 2013;27:193–202.
- Lee JP, Heo NJ, Joo KW, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant. 2010;25:2772–2785.
- Herlenius G, Fistouris J, Olausson M, Felldin M, Bäckman L, Friman S. Early renal function post-liver transplantation is predictive of progressive chronic kidney disease. Scand J Gastroenterol. 2008;43:344–349.
- Garces G, Contreras G, Carvalho D, et al. Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus. Clin Nephrol. 2011;75:150–157.
- Fabrizi F, Dixit V, Martin P, Messa P. Chronic kidney disease after liver transplantation: Recent evidence. Int J Artif Organs. 2010;33:803–811.
- De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. Liver Transpl. 2009;15:1262–1269.
- Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial. Am J Transplant. 2012;12:694–705.
- Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10:2252–2262.
- De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. Am J Transplant. 2012;12:3008–3020.
- Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-Month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233–242.
- Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation. 2011;92:410–418.
- Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation—PROTECT. Am J Transplant. 2012;12:1855–1865.
- Burra P, Senzolo M, Masier A, et al. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. Dig Liver Dis. 2009;41:350–356.
- Cantarovich M, Tchervenkov J, Paraskevas S, et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation. 2011;92:1358–1363.
- Everson GT. Everolimus and mTOR inhibitors in liver transplantation: Opening the “box. Liver Transpl. 2006;12:1571–1573.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470.
- Nankivell BJ, Gruenewald SM, Allen R, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation. 1995;59:1683–1689.
- Sanchez EQ, Melton LB, Chinnakotla S, et al. Predicting renal failure after liver transplantation from measure glomerular filtration rate: Review of up to 15 years of follow-up. Transplantation. 2010;89:232–235.
- Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl. 2003;9:741–747.
- Nashan B. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors. Transplant Rev. 2009;23:47–52.
- Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant. 2013;27:217–226.
- Vallin M, Guillaud O, Morard I, et al. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant. 2011;25:660–669.
Source: PubMed